Neuralink, Elon Musk’s brain chip company, announced that three participants will evaluate its device in a study expected to take a few years.
Last year, local media reported that Neuralink planned to register ten patients when applied to the U.S. regulatory agency for clinical trials.
Neuralink is testing its device to allow paralyzed patients to use digital devices by thought alone, which is believed to be helpful for patients with spinal cord injuries.
The Food and Drug Administration (FDA) generally encourages companies to share their clinical trial information for the public good; however, the FDA and the company executives refused to comment on Neuralink.
This research has a primary due date of 2026, while the entire study is expected to be completed by 2031.
Most Commented